Sun Pharma Q4 net more than doubles to Rs 894 cr on better operational show

Low base supported overall performance; consolidated sales from operations came in at Rs 8,431 crore, up 4.4% YoY

Sun Pharmaceuticals posted a 124 per cent year-on-year (YoY) rise in net profit in the fourth quarter of financial year 2020-21 at Rs 894 crore. This is mainly on operational efficiencies and a low base in the corresponding quarter last year.
 
The company said it is evaluating developing a new pipeline of biosimilars as its R&D focus. It has also requested for an inspection of the Halol site in Gujarat. When compared to Rs 636 crore net profit in Q4 of FY19, the rise is around 40 per cent. The year 2019-20 was partially hit by the Covid-19 pandemic,